Schroders’s Elevance Health ELV Stock Holding History

Schroders’s Portfolio ELV Stock Details ELV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-1,469	Closed	-$709K	–	34
2022 Q2	$709K	Sell	1,469 -838	-36%	-$415K	0.21%	11
2022 Q1	$1.13M	Buy	+2,307	New	+$1.05M	0.25%	16

Other funds holding ELV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Schroders's ELV Position: Q3 2022 in Review

Schroders sold out of Elevance Health (ELV) in Q3 2022, closing a stake of 1,469 shares — an estimated $709K sold.

Schroders first reported a position in ELV in Q1 2022 and held it in 2 quarters. The position peaked at $1.13M in Q1 2022. 1,447 funds tracked by Wall St. Rank hold ELV as of Q3 2022.

Schroders reported no remaining Elevance Health position as of Q3 2022 after selling out during the quarter.
Schroders sold 1,469 Elevance Health shares in Q3 2022, an estimated $709K.
Schroders first reported a position in Elevance Health in Q1 2022 and held it in 2 quarters.
Schroders's Elevance Health position peaked at $1.13M in Q1 2022.
1,447 funds tracked by Wall St. Rank held Elevance Health as of Q3 2022.

Based on Schroders's 13F filing for Q3 2022, filed 24 Oct 2022.